This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
Clinical Summary

Cannabis Therapy Improves Depression Symptoms, Quality of Life, and Sleep Quality


  • Initiation of treatment with cannabis-based medicinal products was associated with significant improvements in depression and anxiety symptoms, health-related quality of life, and sleep quality after 1, 3, and 6 months of treatment.

Why This Matters

  • Medicinal cannabis has gained popularity as a potential new treatment for depression.

Study Design

  • This was an observational case series that included 129 uncontrolled cases of patients with depression, identified using data from the UK Medical Cannabis Registry.
  • Primary outcomes: changes in Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, Sleep Quality Scale, and EQ-5D-5L from baseline to 1, 3, and 6 months.
  • Secondary outcome: incidence of adverse events.
  • Funding: None.

Key Results

  • At 1, 3, and 6 months, there were significant improvements in:
    • Patient Health Questionnaire-9 scores (P<0.001 for all);
    • Generalized Anxiety Disorder-7 scores (P<0.001, P<0.001, and P=0.015, respectively);
    • Sleep Quality Scale (P<0.001, P<0.001, and P=0.029, respectively);
    • EQ-5D-5L usual activities (P<0.001, P<0.001, and P=0.005, respectively);
    • anxiety/depression subscores (P<0.001 for all); and
    • EQ-5D-5L Index Value (P<0.001, P<0.001, and P=0.003, respectively).
  • At 1 and 3 months, statistically significant improvements were observed for EQ-5D-5L:
    • mobility (P=0.003 and P=0.011, respectively);
    • self-care (P=0.009 and P=0.016, respectively); and
    • pain and discomfort (P<0.001 for both).
  • Overall, 153 adverse events were reported, of which 76 (49.7%) were mild, 57 (37.3%) were moderate, and 20 (13.0%) were severe.


  • Observational design.